Dr. Rini on Managing the Toxicity of Pembrolizumab Plus Axitinib in mRCC

Dr Rini on a Biomarker Analysis for Pembrolizumab/Axitinib in Advanced RCCПодробнее

Dr. Rini on Pembrolizumab Plus Axitinib in RCCПодробнее

Pembrolizumab Plus Axitinib in the Second-line and Beyond for mRCCПодробнее

Dr. Rini Discusses the VEGF Targeted Agent AxitinibПодробнее

Dr. Rini on the Results From His Axitinib and Sorafenib TrialПодробнее

Dr. Rini Explains the Axitinib Integration ProcessПодробнее

Dr. Rini on the Efficacy of Axitinib and Pembrolizumab in RCCПодробнее

Dr. Rini Discusses Pembrolizumab Plus Axitinib in mRCCПодробнее

Dr. Rini Describes Axitinib's and Sorafenib's Side EffectsПодробнее

Longer Term Outcomes With Pembrolizumab Plus Axitinib for Advanced RCCПодробнее

Dr. McGregor on Implications of the FDA Approval of Pembrolizumab/Axitinib in RCCПодробнее

Overview of a Phase III Trial of Pembrolizumab Plus Axitinib in RCCПодробнее

Pembrolizumab Plus Axitinib and the Future of Further-line mRCC TreatmentsПодробнее

Dr. Powles on FDA Approval of Pembrolizumab Plus Axitinib in Advanced RCCПодробнее

Dr. Rini Describes Hypertension as a Biomarker in RCCПодробнее

Dr. Rini on Standards of Care for Advanced RCCПодробнее

Dr. Rini on Axitinib for Treatment of Metastatic Renal Cell CarcinomaПодробнее

Dr. Cost on Pembrolizumab Plus Axitinib in Patients With RCCПодробнее

Dr. Vaishampayan on Axitinib Plus Pembrolizumab in Advanced RCCПодробнее